Clinical trials: Human Immunodeficiency Virus Type 1
Infection, Human Immunodeficiency Virus
Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients
This study is a cross sectional observational study to evaluate the prevalence of HLA-B*5701 in the major French ethnotypes. Any HIV-1 infected subject will be eligible for this study including antiretroviral therapy (ART) naÃ-ve…
- Trial name
- NCT00441688
- Testing
- GI265235
- Volunteers
- 974 people
- Sponsor
- ViiV Healthcare
Cognitive Disorders, HIV Infections
HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs
The purpose of this study is to see whether anti-HIV drugs that reduce HIV in the blood also reduce HIV in the cerebrospinal fluid (CSF). CSF is the fluid found around the brain and spinal cord.
- Trial name
- NCT00001103
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines
The object of the study is to assess the safety profile of candidate vaccines ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVcnsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers.
- Trial name
- NCT04586673
- Testing
- ChAdOx1.tHIVconsv1 (C1), MVA.tHIVconsv3 (M3), MVA.tHIVconsv4 (M4)
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Oxford
HIV-1-infection
Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch
Combination antiretroviral therapy (cART) HIV treatments are associated with increased quality of life, and a normalisation of life expectancy in people living with HIV.
- Trial name
- DORDOL (NCT04892654)
- Testing
- Doravirine, Dolutegravir, Triple cART regimen
- Where
- 3 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
HIV-1 Infection
Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
Background: Despite the introduction of highly effective antiretroviral therapy (ART) regimes, which control the HIV infection and results in increases in CD4 cell counts and an undetectable viral load, many patients suffer from…
- Trial name
- NCT01627678
- Testing
- Vacc-C5/GM-CSF, Vacc-C5/Alhydrogel
- Where
- Norway
- Volunteers
- 36 people
- Sponsor
- Bionor Immuno AS
HIV Infections
Immune and Viral Outcomes of HIV-1 Therapy Interruption
The purpose of this study is to determine if stopping anti-HIV drugs for a period of time is safe and effective for enhancing the immune function of patients with HIV.
- Trial name
- NCT00051818
- Testing
- Treatment interruption/reinitiation schedule
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Wistar Institute
HIV, HIV Infections
Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
The objective of this study is to evaluate the safety and efficacy of a regimen containing cobicistat-boosted atazanavir (ATV+COBI) plus emtricitabine/tenofovir disoproxil fumarate (Truvada®; FTC/TDF) fixed-dose combination (FDC)…
- Trial name
- NCT01108510
- Testing
- COBI, RTV, ATV
- Where
- 134 sites in United States, Australia and 17 more
- Volunteers
- 698 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally
This study is the first to try this product in the rectum of humans. This study is only to find out if the gel is safe for use in the rectum, not to see if the gel works.
- Trial name
- NCT00408538
- Testing
- UC-781 microbicide gel (0.1% and 0.25%)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV Infections
Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults
The purpose of this study is to determine the safety of and immune response to a DNA HIV vaccine, pGA2/JS7, followed by a modified vaccinia (smallpox) HIV vaccine, MVA/HIV62, in HIV uninfected adults.
- Trial name
- NCT00301184
- Testing
- pGA2/JS7 DNA, Modified vaccinia Ankara/HIV62
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy…
- Trial name
- NCT06214052
- Testing
- VH4524184, Antiretroviral therapy
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 22 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Patients Who Recently Have Been Infected With HIV
The purpose of this study is to find out if anti-HIV drugs, taken by patients who are newly infected with HIV, can make the level of HIV in the body too low to detect.
- Trial name
- NCT00006415
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (< 50 copies/mL) (c/mL) at 48 weeks (W48) Main Secondary objectives: Comparison of the two arms for genotypic…
- Trial name
- COOL (NCT00643968)
- Testing
- EFV+TDF, EFV+3TC+TDF
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus I Infection, Drug Use
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed
In an effort to engage more HIV-infected PWUD into care, and ensure treatment adherence and efficacy, simplification of older, multi-tablet regimens is required.
- Trial name
- NCT04132674
- Testing
- Bictegravir/emtricitabine/tenofovir alafenamide
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Vancouver Infectious Diseases Centre
Human Immunodeficiency Virus
Tripterygium Wilfordii Hook F (TwHF) Treatment for Immune Non-responders With HIV-1 Infection
HIV-1 infection is characterized by progressive depletion of CD4+ T cells that eventually leads to clinically significant immunodeficiency.
- Trial name
- NCT01666990
- Testing
- TwHF
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Beijing 302 Hospital
HIV Infections
Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials
The purpose of this trial is to determine if exposure to ARV-containing investigational products in IPM clinical trials will impact the natural history of HIV infection as measured by the virologic, immunologic and clinical…
- Trial name
- NCT01618058
- Testing
- No Investigational Product
- Where
- 5 sites in Rwanda, South Africa
- Volunteers
- 151 people
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infections
Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy
This substudy is an open-label, randomised study comparing the uptake of recombinant interleukin-2 (rIL-2) in HIV-1 infected individuals receiving different combinations of antiemetics and analgesic agents during rIL-2 dosing in…
- Trial name
- NCT00147355
- Testing
- ondansetron, ibuprofen, paracetamol, metoclopramide, ibuprofen, paracetamol, Metoclopramide, codeine phosphate, ibuprofen, paracetamol
- Where
- 16 sites in Argentina, Australia and 1 more
- Volunteers
- 28 people
- Sponsor
- Kirby Institute
HIV Infections
Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus
Drug resistance may develop in HIV infected patients who take anti-HIV drugs, but most patients do well if they continue taking them.
- Trial name
- NCT00102934
- Testing
- Enfuvirtide-intensified HAART
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools
To date, all work related to the study of HIV tropism, was performed on HIV B and C subtypes. In the studied samples, HIV variants of subtype A were virtually absent.
- Trial name
- CoTrAST (NCT01823614)
- Where
- Russia
- Volunteers
- 943 people
- Sponsor
- Dmitry Kireev
HIV Infections
A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.
- Trial name
- CABNATE (NCT07275606)
- Testing
- Oral CAB, IM CAB LA
- Where
- South Africa
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV-1 Infection, Hepatitis C
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of the infection when they are treated with sofosbuvir.
- Trial name
- NCT02605304
- Testing
- Ledipasvir/sofosbuvir, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.